查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1701346

Keytruda 市场规模、份额、趋势分析报告：按应用程式、付款人、分销管道、地区、细分市场预测，2025 年至 2030 年

Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma), By Payer (Commercial/Private, Public), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

Keytruda 市场成长与趋势

根据Grand View Research, Inc.的最新报告，预计到2030年全球Keytruda市场规模将达到266.3亿美元，2025年至2030年期间的复合年增长率为-3.23%。

市场的成长轨迹正在略微放缓。然而，联合治疗与化疗、标靶药物和其他免疫疗法联合使用可以改善疗效，从而推动市场向前发展。正在进行的临床试验正在评估其在其他癌症适应症中的疗效，特别是生物标记主导的治疗方法。该药物能够延长三阴性乳癌、肺癌和尿路上皮癌等高难度癌症的无恶化生存期，进一步提升了在市场上的地位。此外，监管活动不断增加，评估 Keytruda 在早期癌症中的价值，加速其在新辅助和辅助治疗中的应用。

儘管Keytruda拥有强大的市场地位，但它也面临挑战，主要是因为专利到期。生物相似药竞争的引入预计会带来定价压力并降低市场独占性。为了解决这个问题，默克公司正在积极推行生命週期管理策略，包括开发更容易管理的皮下製剂作为静脉注射的替代品。最近的 3 期临床试验已证实，Keytruda 的 SC 製剂保持了相当的功效和安全性，有可能扩大其商业性可用性。

竞争格局也在不断演变， Opdivo和TECENTRIQ等 PD-1/PD-L1 抑制剂正在争夺市场占有率。此外，下一代免疫疗法和新治疗方法可能会威胁 Keytruda 的优势。不过，默克对研发和策略合作的持续投入预计将有助于Keytruda保持在肿瘤领域的地位。对于默克公司而言，我们不断努力扩大适应症，探索新的组合方案，并透过创新配方提高患者的便利性，对于维持我们在免疫肿瘤市场的领先地位至关重要。

Keytruda 面临的最大挑战之一是其专利到期，这将为生物相似药市场带来竞争。因此，多家製药公司正在积极开发生物相似药，这可能对默克公司Keytruda的企业收益产生重大影响。随着市场独占权的丧失，我们预计将面临更大的定价压力和报销挑战，特别是在成本敏感的市场。此外，围绕生物相似药核准的监管障碍和诉讼可能会造成市场不确定性。为了降低这些风险，默克专注于生命週期管理策略，例如开发新配方和扩大适应症，以便在生物相似药进入市场后仍能维持需求。

同时，Keytruda 仍然是一个巨大的商机，特别是在联合治疗和早期治疗领域。随着 Keytruda 继续证明对具有某些基因和分子标记的患者有效，向个人化医疗和生物标誌物主导的癌症治疗的转变代表着一个主要的增长途径。研究 KEYTRUDA 与新型药物（如抗体药物复合体和下一代免疫查核点抑制剂）联合治疗的临床试验可能会进一步增强 KEYTRUDA 的治疗潜力。此外，新辅助和辅助治疗的核准将延长治疗时间，扩大目标患者群体并推动持续的需求。

默克公司的另一个关键机会在于开发 Keytruda 的皮下（SC）製剂，旨在提高患者的便利性和可及性。如果核准，这种製剂可以为面临静脉注射障碍（例如难以进入输液中心）的患者提供一种替代方案。此外，SC 配方可以透过提供差异化产品来延缓生物相似药的影响，有助于延长 Keytruda 的市场独占权。此外，亚太和拉丁美洲新兴的肿瘤市场为市场扩张提供了机会，因为癌症发生率的上升和医疗保健基础设施的改善将推动对先进免疫疗法的需求。透过对新适应症、组合方案和创新药物传递方法的策略性投资，默克致力于让 KEYTRUDA 在全球免疫肿瘤市场保持强势地位，儘管未来面临挑战。

Keytruda 市场报告重点

  • 根据应用，肺癌在 2024 年占据 Keytruda 市场的主导地位，收入份额最高，为 27.4%，这得益于其广泛用于非小细胞肺癌 (NSCLC) 和小细胞肺癌 (SCLC) 的一线治疗。另一方面，由于 Keytruda 在三阴性乳癌(TNBC) 中的出现以及正在进行的临床试验以探索其在其他乳癌亚型中的疗效，预计乳癌在预测期内将以最快的复合年增长率增长。
  • 根据付款人，商业/私人保险部分在 2024 年占据最大份额，为 91.0%，这得益于新兴市场对免疫肿瘤疗法的强大报销支持。然而，随着政府医疗保健计划和国家报销政策扩大昂贵癌症治疗的覆盖范围，公共保险业预计将实现稳步增长。
  • 根据分销管道，到 2024 年，医院药房将成为主导市场，占有 51.8% 的份额，由于癌症治疗中心需要管理管理和专家监督，因此占据最高的销售份额。然而，由于越来越多人转向门诊免疫疗法，以及 Keytruda 皮下製剂可能获得批准，核准专科药房在预测期内的复合年增长率将最快，这将提高传统医院环境以外的可及性。
  • 2025年2月，美国食品药物管理局（FDA）对默克公司的生技药品申请（sBLA）授予优先审查权，该申请将Keytruda（ Pembrolizumab ）与标准治疗相结合，作为可切除的局部晚期头颈部鳞状核准癌（LA-HNSCC）患者的手术全期治疗。该决定基于 3 期 KEYNOTE-689 试验，该试验显示，与单独接受标准治疗相比，接受 KEYTRUDA 方案治疗的患者的无事件生存期 (EFS) 和主要病理反应 (mPR) 有统计学上显着改善。 FDA 已将申请的目标行动日期设定为 2025 年 6 月 23 日。

目录

第一章调查方法与范围

第二章执行摘要

第三章 Keytruda 市场变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 专利到期分析
    • 定价和报销方案
    • 併购与交易
    • 学名药/生物相似药的影响

第四章 Keytruda 市场：按应用进行的业务分析

  • 2024 年和 2030 年应用市场占有率
  • 应用程式细分仪表板
  • 市场规模、预测与趋势分析（按应用，2018-2030 年）
  • 肺癌
  • 乳癌
  • 何杰金氏淋巴瘤
  • 头颈癌
  • 胃癌
  • 尿路上皮癌
  • 其他的

5. KEYTRUDA 市场：付款人业务分析

  • 2024 年及 2030 年付款人市场占有率
  • 付款人细分仪表板
  • 2018 年至 2030 年按付款方分類的市场规模、预测与趋势分析
  • 商业/个人
  • 公共

第六章：Keytruda 市场：按分销管道进行的业务分析

  • 2024年及2030年分销通路市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院药房
  • 专业药房

第七章 Keytruda 市场：区域评估与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018年至2030年市场规模及预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章竞争格局

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/列表
    • Merck &Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Regeneron Pharmaceuticals, Inc. &Sanofi SA
    • Pfizer Inc. &Seagen Inc.
    • Amgen Inc.
    • Samsung Bioepis Co., Ltd.
    • Bio-Thera Solutions, Ltd.
Product Code: GVR-4-68040-539-2

Keytruda Market Growth & Trends:

The global Keytruda market size is anticipated to reach USD 26.63 billion by 2030 and is projected to decline at a CAGR of -3.23% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is experiencing a slight decline in the growth trajectory. However, the market is moving ahead due to its effectiveness in combination therapies, enhancing outcomes when used alongside chemotherapy, targeted agents, and other immunotherapies. Ongoing clinical trials are evaluating its efficacy in additional cancer indications, particularly in biomarker-driven treatment approaches. The drug's ability to extend progression-free survival in challenging cancers such as triple-negative breast cancer, lung cancer, and urothelial carcinoma further strengthens its market presence. Additionally, regulatory bodies are increasingly recognizing the value of Keytruda in early-stage cancers, fueling its adoption in neoadjuvant and adjuvant settings.

Despite its strong market foothold, Keytruda faces challenges, primarily due to its upcoming patent expiration in 2028. The introduction of biosimilar competition is expected to create pricing pressures and reduce market exclusivity. To counter this, Merck is actively working on lifecycle management strategies, including the development of a subcutaneous (SC) formulation that offers a more convenient alternative to the intravenous (IV) version. Recent Phase 3 trials have confirmed that SC Keytruda maintains comparable efficacy and safety, potentially extending its commercial viability.

The competitive landscape is also evolving, with rival PD-1/PD-L1 inhibitors, such as Opdivo and Tecentriq, vying for market share. Additionally, next-generation immunotherapies and novel treatment modalities pose potential threats to Keytruda's dominance. However, Merck's ongoing investments in research and development, coupled with strategic collaborations, are expected to sustain Keytruda's relevance in the oncology space. The company's continued efforts to expand indications, explore new combination regimens, and enhance patient accessibility through innovative drug formulations will be crucial in maintaining its leadership in the immuno-oncology market.

One of the biggest challenges Keytruda faces is its impending patent expiration in 2028, which will open the market to biosimilar competition. As a result, several pharmaceutical companies are actively developing biosimilar versions, which could significantly impact Merck's revenue from Keytruda. With the loss of exclusivity, pricing pressures and reimbursement challenges are expected to intensify, particularly in cost-sensitive markets. Additionally, regulatory hurdles and litigation over biosimilar approvals could create market uncertainties. To mitigate these risks, Merck is focusing on life cycle management strategies, including the development of new formulations and expanded indications to sustain demand even after biosimilar entry.

At the same time, opportunities remain strong for Keytruda, particularly in combination therapies and earlier treatment lines. The shift toward personalized medicine and biomarker-driven oncology treatments presents a significant growth avenue, as Keytruda continues to demonstrate efficacy in patients with specific genetic and molecular markers. Clinical trials exploring Keytruda in combination with novel agents, such as antibody-drug conjugates and next-generation immune checkpoint inhibitors, could further enhance its therapeutic potential. Moreover, approvals in neoadjuvant and adjuvant settings are expected to increase treatment durations and expand the eligible patient pool, ensuring continued demand.

Another key opportunity for Merck lies in the development of the subcutaneous (SC) formulation of Keytruda, which aims to improve patient convenience and access. If approved, this version could offer an alternative for patients who face barriers to IV administration, such as limited access to infusion centers. The SC formulation could also help extend Keytruda's market exclusivity by offering a differentiated product that may delay the impact of biosimilars. Additionally, emerging oncology markets in Asia-Pacific and Latin America present expansion opportunities, as rising cancer prevalence and improving healthcare infrastructure drive demand for advanced immunotherapies. With strategic investments in new indications, combination regimens, and innovative drug delivery methods, Merck is positioning Keytruda to maintain its strong presence in the global immuno-oncology market, despite the challenges ahead.

Keytruda Market Report Highlights:

  • Based on application, lung cancer dominated the Keytruda market in 2024 with the largest revenue share of 27.4%, due to its widespread adoption as a first-line treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Meanwhile, breast cancer is projected to grow at the fastest CAGR over the forecast period, driven by Keytruda's increasing use in triple-negative breast cancer (TNBC) and ongoing clinical trials exploring its efficacy in other breast cancer subtypes.
  • Based on payer, the commercial/private insurance segment held the largest share of 91.0% in 2024, owing to strong reimbursement support for immuno-oncology therapies in developed markets. However, the public insurance segment is expected to see steady growth as government healthcare programs and national reimbursement policies expand access to costly cancer treatments.
  • Based on distribution channel, hospital pharmacies emerged as the dominant segment with a share of 51.8% in 2024, accounting for the highest revenue share due to the need for controlled administration and specialist supervision in oncology treatment centers. Meanwhile, specialty pharmacies are projected to witness the fastest CAGR over the forecast period, driven by the growing shift towards outpatient immunotherapy administration and potential approval of the subcutaneous Keytruda formulation, which could improve accessibility outside traditional hospital settings.
  • In February 2025, the U.S. Food and Drug Administration (FDA) granted Priority Review to Merck's supplemental Biologics License Application (sBLA) for Keytruda (pembrolizumab) in combination with standard care as a perioperative treatment for patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This decision is based on the Phase 3 KEYNOTE-689 trial, which demonstrated a statistically significant improvement in event-free survival (EFS) and major pathological response (mPR) for patients receiving the Keytruda regimen compared to standard treatment alone. The FDA has set a target action date of June 23, 2025, for this application.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Payer
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Keytruda Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Patent Expiry Analysis
    • 3.3.4. Pricing and Reimbursement Scenario
    • 3.3.5. M&A and Deals
    • 3.3.6. Impact of Generics/Biosimilars

Chapter 4. Keytruda Market: Application Business Analysis

  • 4.1. Application Market Share, 2024 & 2030
  • 4.2. Application Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 4.4. Lung Cancer
    • 4.4.1. Lung Cancer Market, 2018 - 2030 (USD Million)
  • 4.5. Breast Cancer
    • 4.5.1. Breast Cancer Market, 2018 - 2030 (USD Million)
  • 4.6. Hodgkin Lymphoma
    • 4.6.1. Hodgkin Lymphoma Market, 2018 - 2030 (USD Million)
  • 4.7. Head and Neck Cancer
    • 4.7.1. Head and Neck Cancer Market, 2018 - 2030 (USD Million)
  • 4.8. Gastric Cancer
    • 4.8.1. Gastric Cancer Market, 2018 - 2030 (USD Million)
  • 4.9. Urothelial Cancer
    • 4.9.1. Urothelial Cancer Market, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Keytruda Market: Payer Business Analysis

  • 5.1. Payer Market Share, 2024 & 2030
  • 5.2. Payer Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Payer, 2018 to 2030 (USD Million)
  • 5.4. Commercial/Private
    • 5.4.1. Commercial/Private Market, 2018 - 2030 (USD Million)
  • 5.5. Public
    • 5.5.1. Public Market, 2018 - 2030 (USD Million)

Chapter 6. Keytruda Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.5. Specialty Pharmacy
    • 6.5.1. Specialty Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 7. Keytruda Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 7.4. North America
    • 7.4.1. North America Keytruda Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Keytruda Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Keytruda Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Bristol-Myers Squibb Company
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-La Roche Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Regeneron Pharmaceuticals, Inc. & Sanofi S.A.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer Inc. & Seagen Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Amgen Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Samsung Bioepis Co., Ltd.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Bio-Thera Solutions, Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Keytruda market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 5 Global Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 6 Global Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 7 Global Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 North America Keytruda market, by country, 2018 - 2030 (USD Million)
  • Table 9 North America Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 10 North America Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 11 North America Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 12 North America Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 14 U.S. Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.S. Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 16 U.S. Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Canada Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 18 Canada Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 19 Canada Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 20 Canada Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21 Mexico Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 22 Mexico Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 23 Mexico Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 24 Mexico Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Europe Keytruda market, by country, 2018 - 2030 (USD Million)
  • Table 26 Europe Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 27 Europe Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 28 Europe Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 29 Europe Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 UK Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 31 UK Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 32 UK Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 33 UK Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Germany Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 35 Germany Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 37 Germany Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38 France Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 39 France Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 40 France Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 41 France Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Italy Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 43 Italy Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 44 Italy Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 45 Italy Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46 Spain Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 47 Spain Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 48 Spain Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 49 Spain Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Norway Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 51 Norway Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 52 Norway Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 53 Norway Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Denmark Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 55 Denmark Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 56 Denmark Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 57 Denmark Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 Sweden Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 59 Sweden Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 60 Sweden Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 61 Sweden Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Asia-Pacific Keytruda market, by country, 2018 - 2030 (USD Million)
  • Table 63 Asia-Pacific Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 64 Asia-Pacific Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 65 Asia-Pacific Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 66 Asia-Pacific Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Japan Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 68 Japan Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 69 Japan Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 70 Japan Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 China Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 72 China Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 73 China Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 74 China Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 India Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 76 India Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 77 India Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 78 India Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Australia Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 80 Australia Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 81 Australia Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 82 Australia Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83 South Korea Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 84 South Korea Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Korea Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 86 South Korea Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Thailand Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 88 Thailand Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 89 Thailand Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 90 Thailand Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Latin America Keytruda market, by country, 2018 - 2030 (USD Million)
  • Table 92 Latin America Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 93 Latin America Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 94 Latin America Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 95 Brazil Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 96 Brazil Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 97 Brazil Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 98 Brazil Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99 Argentina Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 100 Argentina Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 101 Argentina Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 102 Argentina Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa (MEA) Keytruda market, by country, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108 South Africa Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 109 South Africa Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 110 South Africa Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 111 South Africa Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 UAE Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 117 UAE Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 118 UAE Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 119 UAE Keytruda market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Keytruda market, by type, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Keytruda market, by application, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Keytruda market, by dosage form, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Keytruda market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Keytruda market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Keytruda market dynamics
  • Fig. 12 Keytruda market: Porter's five forces analysis
  • Fig. 13 Keytruda market: PESTLE analysis
  • Fig. 14 Keytruda market revenue by application, 2018 - 2030
  • Fig. 15 Lung cancer market outlook (USD Million)
  • Fig. 16 Breast cancer market growth trend (USD Million)
  • Fig. 17 Melanoma treatment market analysis (USD Million)
  • Fig. 18 Hodgkin lymphoma treatment market size (USD Million)
  • Fig. 19 Head and neck cancer Keytruda market share (USD Million)
  • Fig. 20 Gastric cancer Keytruda market revenue (USD Million)
  • Fig. 21 Urothelial cancer Keytruda market demand (USD Million)
  • Fig. 22 Other cancer applications for Keytruda (USD Million)
  • Fig. 23 Keytruda market revenue by payer type, 2018 - 2030
  • Fig. 24 Commercial/private insurance market share for Keytruda (USD Million)
  • Fig. 25 Public insurance market growth for Keytruda (USD Million)
  • Fig. 26 Keytruda market revenue by distribution channel, 2018 - 2030
  • Fig. 27 Hospital pharmacy Keytruda market analysis (USD Million)
  • Fig. 28 Specialty pharmacy Keytruda market growth trend (USD Million)
  • Fig. 29 Keytruda market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. country dynamics
  • Fig. 33 U.S. Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 55 Asia-Pacific Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 68 Latin America Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 73 Middle East & Africa (MEA) Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework